Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H; Risedronate Phase III Research Group. Fukunaga M, et al. Among authors: ohashi y. Osteoporos Int. 2002 Dec;13(12):971-9. doi: 10.1007/s001980200135. Osteoporos Int. 2002. PMID: 12459940 Clinical Trial.
Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma.
Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, Kinoshita T, Hotta T, Aikawa K, Tsushita K, Hiraoka A, Matsuno Y, Nakamura S, Mori S, Ohashi Y; IDEC-C2B8 Japan Study Group. Tobinai K, et al. Among authors: ohashi y. Ann Oncol. 2004 May;15(5):821-30. doi: 10.1093/annonc/mdh176. Ann Oncol. 2004. PMID: 15111353 Free article. Clinical Trial.
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients.
Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. Shitara K, et al. Among authors: ohashi y. Ann Oncol. 2019 Feb 1;30(2):259-265. doi: 10.1093/annonc/mdy526. Ann Oncol. 2019. PMID: 30508156 Free article. Clinical Trial.
Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.
Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C, et al. Kawai S, et al. Among authors: ohashi y. Cancer Chemother Pharmacol. 1992;31 Suppl:S1-6. doi: 10.1007/BF00687096. Cancer Chemother Pharmacol. 1992. PMID: 1281041 Clinical Trial.
Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cooperative Study Group for Liver Cancer Treatment of Japan.
Kawai S, Tani M, Okamura J, Ogawa M, Ohashi Y, Monden M, Hayashi S, Inoue J, Kawarada Y, Kusano M, et al. Kawai S, et al. Among authors: ohashi y. Cancer Chemother Pharmacol. 1994;33 Suppl:S97-102. doi: 10.1007/BF00686677. Cancer Chemother Pharmacol. 1994. PMID: 7511070 Clinical Trial.
Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of L-TAE with Farmorubicin and L-TAE with adriamycin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.
Okamura J, Kawai S, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C, et al. Okamura J, et al. Among authors: ohashi y. Cancer Chemother Pharmacol. 1992;31 Suppl:S20-4. doi: 10.1007/BF00687099. Cancer Chemother Pharmacol. 1992. PMID: 1333903 Clinical Trial.
2,187 results